Study Group: Generic Pharmaceuticals Regulation Experts: Healthcare Consultants
Council Members in this Study Group: 45
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Eric GruffPrincipal
E4 Consulting
Eric Gruff, PhD, MBA, BS, is Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 17 years of experience in the pharmaceutical and biotech sector, including...
- Evan Siegel
Adjunct Professor
THE UNIVERSITY OF QUEENSLANDEvan Siegel, M Phil, Ph D, is the President and Chief Executive Officer of Ground Zero Pharmaceuticals, a regulatory affairs and product development consulting firm in California, since June 1999. Dr. Siegel is also an Adjunct Professor at the University...
David ZimmermanPresident/Owner
Doctors of Pharmacy, Inc.David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30...
- Michael Sosnowik
President
MSS Consultants, LLCMichael Sosnowik, PD, Pharmacist and former C-Level executive in pharma distribution, is the President of MSS Consultants, an independent consulting firm to pharmaceutical manufacturers, distributors as well as managed care providers, in New York, since...
Jim FarleyPresident
Cardinal Consulting and TrainingJim Farley is an Independent Consultant and Owner of Cardinal Consulting and Training. Formerly, Mr. Farley served as the Director of the Science Branch of Philadelphia District FDA. He has over 30 years of experience in pharmaceutical and pharmaceutical...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Thriving in a time of adversity - Sun Pharma pounces on shortage by getting approval on Oxycodone
April 13, 2009
Analysis by: Aemad Aslam, President,Sun Pharma gets USFDA's nod to market painkillers | www.hindu.com
Sun Pharma can greatly benefit from the nationwide shortage of Oxycodone Immediate Release Tablet, by getting approval from the FDA on their own generic. With recent recalls from different manufacturers, and the shortage of a comparable product Morphine Sulphate, the FDA currently estimates that return to normal supply levels of Oxycodone may occur in approximately 2 months, during which time Sun Pharma can capitalize on the shortage by securing longer term contracts with wholesalers.
-
Aurobindo Pharma's Escitalopram will be a big mover ... when it comes out in 2011
March 5, 2009
Analysis by: Aemad Aslam, President,Aurobindo Pharma receives tentative approval for Escitalopram | www.indiainfoline.com
Forest's Lexapro commands a $2.5+ billion USD market share, just in the US. Due to such a high volume of the brand product, Aurobindo's tentative approval on Lexapro's generic Escitalopram will be a great opportunity - primarily if they can procure a 6 month period of exclusivity from the FDA. Additionally, despite being a brand name product, Lexapro holds an 8%+ year over year increase in the past 3 years. Hence, the market for the drug in September of 2011 when the patent runs out will be closer to a $3 billion market.
-
Teva's Generic Imitrex commands market of Sumatriptan
February 26, 2009
Analysis by: Aemad Aslam, President,Teva Announces Approval and Launch of Generic Imitrex(R) Tablets | www.pipelinereview.com
With the 180 day exclusivity, Teva is already commanding the market of the generic Imitrex - Sumatriptan oral tablets. Teva maintains an AB rating of the generic that will render most insurance companies to push brand name Imitrex by GlaxoSmithKline to a non-formulary tier, skyrocketing the generic's sales. Already, different wholesalers are reporting a backorder on Teva's generics. Additionally, Teva's pricing point is very favorable to itself, despite Dr Reddy's prior entrance.
-
Acquisitions of Indian Pharma on the extended horizon by Brand name pharma
February 23, 2009
Analysis by: Aemad Aslam, President,Pharma cos on lookout for Indian drug firms | economictimes.indiatimes.com
Acquisitions of various Indian generic pharmaceuticals is likely on the horizon for brand name manufacturers. However, this is not an immediate concern. I would see more consolidations in the US and other Western markets first.
-
Sun Pharma - much stronger with acquisitions including Taro
February 17, 2009
Analysis by: Aemad Aslam, President,As valuations dip, Sun Pharma is in M&A mode | economictimes.indiatimes.com
Sun Pharma is attempting to gain market share in the world largest market - the US market. Sun Pharma is clearly expanding it product base with venturing into topical (dermatological) and pediatric segments, and with vertical integration as with raw materials suppliers. Sequentially, I would see SunPharma to be a leader in the US market within this decade, unless other Indian manufacturers encroach in this market.
Members in this Study Group include these company types:
- Consultancy, Pharma-Focused
- Individual/Small Consultancy
- Consultancy, Healthcare-Focused
- Academic Institution*
- Pharmaceuticals Manufacturer
- Healthcare Management
Members in this Study Group often have these job titles:
- President
- Consultant
- Owner
- Principal
- Professor
- Managing Director
- Director
- Chief Executive Officer
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
October 26, 2006 | Palo Alto
GLGi: New Drug Application ProcessGLG Webcasts & Teleconferences
Leading Experts in Generic Pharmaceuticals Regulation Experts: Healthcare Consultants have not participated in any GLG webcasts.